| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorodeoxyglucose F18 | 30 | 2022 | 2025 | 2.410 |
Why?
|
| Positron-Emission Tomography | 40 | 2023 | 6585 | 2.020 |
Why?
|
| Gastrointestinal Stromal Tumors | 14 | 2019 | 617 | 1.550 |
Why?
|
| Piperazines | 16 | 2014 | 2522 | 1.140 |
Why?
|
| Nuclear Medicine | 2 | 2021 | 257 | 1.050 |
Why?
|
| Pyrimidines | 15 | 2014 | 3026 | 0.970 |
Why?
|
| Proto-Oncogene Proteins c-kit | 13 | 2019 | 726 | 0.940 |
Why?
|
| Radiopharmaceuticals | 20 | 2022 | 2682 | 0.840 |
Why?
|
| Gastrointestinal Neoplasms | 6 | 2019 | 955 | 0.830 |
Why?
|
| Tomography, X-Ray Computed | 29 | 2023 | 20600 | 0.740 |
Why?
|
| Benzamides | 15 | 2014 | 1370 | 0.690 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2019 | 128 | 0.620 |
Why?
|
| Database Management Systems | 1 | 2019 | 256 | 0.610 |
Why?
|
| Tomography, Emission-Computed | 3 | 2008 | 1123 | 0.590 |
Why?
|
| Octreotide | 2 | 2018 | 154 | 0.590 |
Why?
|
| Receptors, Somatostatin | 1 | 2018 | 137 | 0.580 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2019 | 380 | 0.570 |
Why?
|
| Gallium Radioisotopes | 4 | 2022 | 195 | 0.540 |
Why?
|
| Oncology Service, Hospital | 1 | 2016 | 57 | 0.510 |
Why?
|
| Melanoma | 7 | 2015 | 5694 | 0.510 |
Why?
|
| Neoplasms | 21 | 2022 | 22125 | 0.510 |
Why?
|
| Image Enhancement | 3 | 2018 | 2888 | 0.500 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 647 | 0.480 |
Why?
|
| Mucous Membrane | 3 | 2015 | 659 | 0.460 |
Why?
|
| Quinazolines | 4 | 2019 | 1371 | 0.460 |
Why?
|
| Diagnostic Imaging | 8 | 2017 | 3535 | 0.460 |
Why?
|
| Hodgkin Disease | 6 | 2010 | 1378 | 0.450 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 818 | 0.450 |
Why?
|
| Antineoplastic Agents | 22 | 2016 | 13630 | 0.450 |
Why?
|
| Pyrazines | 1 | 2019 | 1202 | 0.450 |
Why?
|
| Imidazoles | 1 | 2019 | 1173 | 0.440 |
Why?
|
| Practice Guidelines as Topic | 5 | 2018 | 7400 | 0.430 |
Why?
|
| Gallium | 2 | 2004 | 28 | 0.400 |
Why?
|
| Lymphoma, Follicular | 3 | 2013 | 457 | 0.400 |
Why?
|
| Radiotherapy | 2 | 2018 | 1498 | 0.390 |
Why?
|
| Radiology Department, Hospital | 1 | 2016 | 407 | 0.390 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2019 | 5662 | 0.390 |
Why?
|
| Pyrroles | 10 | 2016 | 1125 | 0.390 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2013 | 147 | 0.390 |
Why?
|
| Ultrasonography, Mammary | 1 | 2013 | 239 | 0.380 |
Why?
|
| Medical Oncology | 3 | 2015 | 2316 | 0.380 |
Why?
|
| Radiology | 3 | 2017 | 2114 | 0.380 |
Why?
|
| Ureteral Neoplasms | 1 | 2011 | 107 | 0.340 |
Why?
|
| Indoles | 10 | 2016 | 1830 | 0.340 |
Why?
|
| Iodine Radioisotopes | 14 | 1998 | 1030 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 11 | 2015 | 9185 | 0.330 |
Why?
|
| Immunotherapy | 6 | 2021 | 4642 | 0.330 |
Why?
|
| Idoxuridine | 8 | 1998 | 111 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2015 | 11732 | 0.320 |
Why?
|
| Urothelium | 1 | 2011 | 269 | 0.320 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2010 | 126 | 0.310 |
Why?
|
| Pancreatitis | 1 | 2015 | 1097 | 0.310 |
Why?
|
| Glioblastoma | 3 | 2018 | 3481 | 0.300 |
Why?
|
| Lung Neoplasms | 6 | 2022 | 13382 | 0.300 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 940 | 0.290 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2293 | 0.280 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 4 | 2021 | 1130 | 0.280 |
Why?
|
| Paraganglioma | 1 | 2008 | 143 | 0.270 |
Why?
|
| Heart Neoplasms | 2 | 2008 | 364 | 0.270 |
Why?
|
| Liver Neoplasms | 3 | 2019 | 4308 | 0.270 |
Why?
|
| Mutation | 10 | 2019 | 30006 | 0.270 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 2757 | 0.260 |
Why?
|
| Muscles | 1 | 2011 | 1567 | 0.260 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 8000 | 0.250 |
Why?
|
| Humans | 113 | 2023 | 761098 | 0.250 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2010 | 491 | 0.250 |
Why?
|
| Kidney Neoplasms | 5 | 2014 | 4251 | 0.240 |
Why?
|
| Computer Simulation | 1 | 2018 | 6225 | 0.240 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 993 | 0.240 |
Why?
|
| Dihydrotestosterone | 2 | 2023 | 195 | 0.230 |
Why?
|
| Treatment Outcome | 29 | 2019 | 64670 | 0.230 |
Why?
|
| Neoplasm Staging | 13 | 2023 | 11118 | 0.230 |
Why?
|
| Molecular Imaging | 1 | 2011 | 819 | 0.220 |
Why?
|
| Middle Aged | 57 | 2021 | 220835 | 0.220 |
Why?
|
| Thoracic Neoplasms | 2 | 2016 | 268 | 0.220 |
Why?
|
| Education, Medical | 1 | 2015 | 1725 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 2 | 2010 | 1051 | 0.210 |
Why?
|
| Brain Neoplasms | 6 | 2018 | 9025 | 0.210 |
Why?
|
| Mammography | 1 | 2013 | 2430 | 0.210 |
Why?
|
| Aged, 80 and over | 28 | 2017 | 58946 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 3591 | 0.210 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2011 | 2223 | 0.210 |
Why?
|
| Aged | 51 | 2021 | 169266 | 0.200 |
Why?
|
| Female | 75 | 2023 | 392458 | 0.200 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2002 | 36 | 0.200 |
Why?
|
| Phenylurea Compounds | 3 | 2016 | 529 | 0.200 |
Why?
|
| Patient Care Team | 1 | 2013 | 2513 | 0.200 |
Why?
|
| Adult | 52 | 2019 | 221083 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2014 | 2047 | 0.190 |
Why?
|
| Catheterization, Central Venous | 2 | 2009 | 526 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2015 | 9278 | 0.180 |
Why?
|
| Ovarian Neoplasms | 6 | 2017 | 4853 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 2827 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 2 | 2005 | 2896 | 0.180 |
Why?
|
| Breast Neoplasms | 7 | 2023 | 20981 | 0.170 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2012 | 1372 | 0.170 |
Why?
|
| Neoplasm Metastasis | 5 | 2015 | 4908 | 0.170 |
Why?
|
| Electron Transport Complex II | 1 | 2019 | 53 | 0.170 |
Why?
|
| Citrates | 1 | 2000 | 133 | 0.170 |
Why?
|
| Male | 58 | 2019 | 360675 | 0.160 |
Why?
|
| Multiple Myeloma | 3 | 2016 | 5145 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2018 | 36418 | 0.160 |
Why?
|
| Stromal Cells | 3 | 2003 | 1329 | 0.160 |
Why?
|
| Contrast Media | 6 | 2018 | 5311 | 0.150 |
Why?
|
| Receptors, Androgen | 2 | 2023 | 1077 | 0.150 |
Why?
|
| Genotype | 2 | 2016 | 12983 | 0.150 |
Why?
|
| Pyridines | 4 | 2016 | 2872 | 0.150 |
Why?
|
| Lymphatic Metastasis | 3 | 2017 | 2913 | 0.150 |
Why?
|
| Consent Forms | 1 | 2018 | 55 | 0.150 |
Why?
|
| Receptor, erbB-2 | 4 | 2015 | 2553 | 0.140 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2014 | 3163 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2010 | 5318 | 0.140 |
Why?
|
| Rabbits | 7 | 2019 | 4749 | 0.140 |
Why?
|
| Tumor Burden | 3 | 2015 | 1892 | 0.140 |
Why?
|
| Venous Thrombosis | 2 | 2009 | 1304 | 0.130 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 314 | 0.130 |
Why?
|
| Whole Body Imaging | 2 | 2008 | 284 | 0.130 |
Why?
|
| Lymphatic System | 1 | 1997 | 253 | 0.120 |
Why?
|
| Cerebrospinal Fluid | 1 | 2018 | 544 | 0.120 |
Why?
|
| Surgical Flaps | 3 | 2001 | 1670 | 0.120 |
Why?
|
| Gadolinium DTPA | 1 | 2018 | 823 | 0.120 |
Why?
|
| Comprehensive Health Care | 1 | 2016 | 123 | 0.120 |
Why?
|
| Radionuclide Imaging | 12 | 2017 | 1989 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2016 | 3493 | 0.120 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2016 | 664 | 0.120 |
Why?
|
| Sensitivity and Specificity | 6 | 2016 | 14676 | 0.120 |
Why?
|
| Research Report | 1 | 2017 | 367 | 0.110 |
Why?
|
| Diagnosis, Differential | 6 | 2013 | 12975 | 0.110 |
Why?
|
| Retrospective Studies | 18 | 2018 | 80673 | 0.110 |
Why?
|
| Disease-Free Survival | 6 | 2016 | 6817 | 0.110 |
Why?
|
| Prognosis | 13 | 2017 | 29672 | 0.110 |
Why?
|
| Radioimmunotherapy | 1 | 2013 | 91 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2023 | 4060 | 0.100 |
Why?
|
| Immunoglobulin G | 7 | 2008 | 4538 | 0.100 |
Why?
|
| Indium Radioisotopes | 5 | 1999 | 113 | 0.100 |
Why?
|
| Models, Organizational | 1 | 2016 | 544 | 0.100 |
Why?
|
| Statistics, Nonparametric | 3 | 2016 | 2855 | 0.100 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 641 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 3700 | 0.100 |
Why?
|
| Antibodies, Neoplasm | 2 | 2014 | 282 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2015 | 549 | 0.100 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2012 | 240 | 0.100 |
Why?
|
| Binding Sites, Antibody | 2 | 1991 | 337 | 0.090 |
Why?
|
| Sunlight | 1 | 2013 | 337 | 0.090 |
Why?
|
| Taxoids | 1 | 2014 | 668 | 0.090 |
Why?
|
| Li-Fraumeni Syndrome | 2 | 2011 | 117 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2016 | 5300 | 0.090 |
Why?
|
| Sarcoma | 4 | 2009 | 1800 | 0.090 |
Why?
|
| Piperidines | 1 | 2019 | 1656 | 0.090 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1991 | 340 | 0.090 |
Why?
|
| Disease Progression | 3 | 2016 | 13506 | 0.090 |
Why?
|
| Neoplasm, Residual | 3 | 2012 | 1008 | 0.090 |
Why?
|
| Tissue Distribution | 7 | 2018 | 2262 | 0.090 |
Why?
|
| Exons | 2 | 2014 | 2380 | 0.090 |
Why?
|
| Bone Neoplasms | 3 | 2017 | 2527 | 0.090 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 3 | 2009 | 368 | 0.080 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2012 | 237 | 0.080 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2011 | 246 | 0.080 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1996 | 782 | 0.080 |
Why?
|
| Barium Sulfate | 1 | 2009 | 180 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 4021 | 0.080 |
Why?
|
| Gene Amplification | 1 | 2013 | 1084 | 0.080 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 1116 | 0.080 |
Why?
|
| Reproducibility of Results | 6 | 2017 | 20120 | 0.080 |
Why?
|
| Biological Transport | 2 | 2012 | 2082 | 0.080 |
Why?
|
| Drug Administration Schedule | 5 | 2014 | 4849 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 1458 | 0.070 |
Why?
|
| Radioimmunoassay | 1 | 1988 | 861 | 0.070 |
Why?
|
| Regeneration | 1 | 1997 | 1505 | 0.070 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 1365 | 0.070 |
Why?
|
| Lymphoma | 1 | 1997 | 1898 | 0.070 |
Why?
|
| Thoracic Wall | 1 | 2010 | 202 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 3725 | 0.070 |
Why?
|
| Neoplasms, Experimental | 2 | 1990 | 1225 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 401 | 0.070 |
Why?
|
| Jaw Diseases | 1 | 2008 | 92 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2023 | 9001 | 0.070 |
Why?
|
| Young Adult | 7 | 2019 | 59199 | 0.070 |
Why?
|
| Lymphoma, T-Cell | 1 | 2009 | 303 | 0.070 |
Why?
|
| Pulmonary Embolism | 2 | 2011 | 2571 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 16947 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2008 | 273 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 628 | 0.070 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2010 | 474 | 0.070 |
Why?
|
| Survival Rate | 6 | 2013 | 12727 | 0.070 |
Why?
|
| Osteonecrosis | 1 | 2008 | 230 | 0.070 |
Why?
|
| Forecasting | 1 | 2015 | 2928 | 0.070 |
Why?
|
| Skin Neoplasms | 3 | 2015 | 5809 | 0.070 |
Why?
|
| Doxorubicin | 4 | 2012 | 2224 | 0.060 |
Why?
|
| Autoradiography | 7 | 1996 | 729 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 585 | 0.060 |
Why?
|
| Computational Biology | 1 | 2017 | 3499 | 0.060 |
Why?
|
| Neoplasms, Adipose Tissue | 1 | 2005 | 12 | 0.060 |
Why?
|
| Animals | 25 | 2019 | 168083 | 0.060 |
Why?
|
| Subtraction Technique | 1 | 2008 | 518 | 0.060 |
Why?
|
| Adolescent | 11 | 2019 | 88271 | 0.060 |
Why?
|
| Boston | 2 | 2016 | 9324 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 2372 | 0.060 |
Why?
|
| Lung | 4 | 2010 | 9979 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 18217 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2011 | 2359 | 0.060 |
Why?
|
| Needs Assessment | 1 | 2010 | 1139 | 0.060 |
Why?
|
| Vincristine | 2 | 2012 | 1036 | 0.060 |
Why?
|
| Muscle Neoplasms | 1 | 2005 | 130 | 0.060 |
Why?
|
| Radiography | 4 | 2011 | 6975 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2019 | 7969 | 0.060 |
Why?
|
| Spleen | 1 | 1990 | 2290 | 0.060 |
Why?
|
| Biopsy | 3 | 2012 | 6781 | 0.060 |
Why?
|
| Lymph Nodes | 3 | 2023 | 3461 | 0.060 |
Why?
|
| Curriculum | 1 | 2017 | 3739 | 0.060 |
Why?
|
| Prostatic Neoplasms | 3 | 2017 | 11103 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2018 | 6390 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2021 | 8639 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 2813 | 0.050 |
Why?
|
| Diphosphonates | 1 | 2008 | 636 | 0.050 |
Why?
|
| Rats, Inbred F344 | 4 | 1999 | 826 | 0.050 |
Why?
|
| Iohexol | 2 | 2016 | 205 | 0.050 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 1987 | 433 | 0.050 |
Why?
|
| Recurrence | 4 | 2010 | 8456 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 3 | 2018 | 5366 | 0.050 |
Why?
|
| Time Factors | 8 | 2012 | 39953 | 0.050 |
Why?
|
| Random Allocation | 2 | 2004 | 2393 | 0.050 |
Why?
|
| Prednisone | 2 | 2012 | 1565 | 0.050 |
Why?
|
| Mice | 13 | 2018 | 81324 | 0.050 |
Why?
|
| Observer Variation | 3 | 2013 | 2611 | 0.050 |
Why?
|
| Remission Induction | 3 | 2017 | 2392 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2009 | 2426 | 0.050 |
Why?
|
| Insulinoma | 3 | 1991 | 121 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2008 | 961 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 2012 | 39121 | 0.050 |
Why?
|
| Actuarial Analysis | 1 | 2000 | 372 | 0.050 |
Why?
|
| Bone Density Conservation Agents | 1 | 2008 | 795 | 0.040 |
Why?
|
| Cyclophosphamide | 2 | 2012 | 2219 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 1987 | 1152 | 0.040 |
Why?
|
| Social Support | 1 | 2010 | 2175 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2009 | 1158 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2016 | 3429 | 0.040 |
Why?
|
| Mice, Nude | 5 | 2001 | 3604 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2010 | 2218 | 0.040 |
Why?
|
| Isotope Labeling | 2 | 1992 | 393 | 0.040 |
Why?
|
| Treatment Failure | 3 | 2012 | 2643 | 0.040 |
Why?
|
| Predictive Value of Tests | 5 | 2016 | 15308 | 0.040 |
Why?
|
| Neck | 1 | 2004 | 734 | 0.040 |
Why?
|
| Phlebography | 1 | 2000 | 326 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2008 | 2242 | 0.040 |
Why?
|
| Genomics | 1 | 2015 | 5828 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 2008 | 1156 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 1784 | 0.040 |
Why?
|
| Reference Standards | 1 | 2022 | 1005 | 0.040 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2012 | 168 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2015 | 1089 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 12467 | 0.040 |
Why?
|
| Fluorine Radioisotopes | 1 | 2021 | 420 | 0.040 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1998 | 109 | 0.040 |
Why?
|
| Equipment Failure | 1 | 2000 | 579 | 0.040 |
Why?
|
| Gliosarcoma | 1 | 1998 | 114 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2014 | 883 | 0.040 |
Why?
|
| Radiometry | 1 | 2023 | 812 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2012 | 8529 | 0.040 |
Why?
|
| Somatostatin | 1 | 1999 | 447 | 0.040 |
Why?
|
| Liver | 2 | 1990 | 7513 | 0.040 |
Why?
|
| Technetium Compounds | 1 | 1997 | 15 | 0.040 |
Why?
|
| Antimony | 1 | 1997 | 20 | 0.040 |
Why?
|
| Colloids | 1 | 1997 | 123 | 0.030 |
Why?
|
| Nitriles | 2 | 2014 | 971 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 4340 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 1998 | 247 | 0.030 |
Why?
|
| Survival Analysis | 5 | 2016 | 10083 | 0.030 |
Why?
|
| Methylnitrosourea | 1 | 1996 | 30 | 0.030 |
Why?
|
| Hemangiosarcoma | 1 | 1998 | 215 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 10755 | 0.030 |
Why?
|
| Bleomycin | 2 | 2009 | 494 | 0.030 |
Why?
|
| United States | 5 | 2017 | 72337 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 2008 | 3812 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 3512 | 0.030 |
Why?
|
| Kidney | 1 | 2011 | 7034 | 0.030 |
Why?
|
| Diaphragm | 1 | 2017 | 351 | 0.030 |
Why?
|
| Vinblastine | 2 | 2009 | 488 | 0.030 |
Why?
|
| Artifacts | 2 | 2018 | 1913 | 0.030 |
Why?
|
| Antigens, Surface | 2 | 1991 | 1607 | 0.030 |
Why?
|
| Isoelectric Focusing | 1 | 1995 | 149 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2015 | 41486 | 0.030 |
Why?
|
| ROC Curve | 2 | 2014 | 3582 | 0.030 |
Why?
|
| Models, Animal | 1 | 2001 | 2114 | 0.030 |
Why?
|
| Dacarbazine | 2 | 2009 | 559 | 0.030 |
Why?
|
| Rats | 7 | 2007 | 23713 | 0.030 |
Why?
|
| Radioimmunodetection | 1 | 1993 | 45 | 0.030 |
Why?
|
| Carcinogens | 1 | 1996 | 452 | 0.030 |
Why?
|
| Adsorption | 2 | 1990 | 197 | 0.030 |
Why?
|
| Osteomyelitis | 1 | 1997 | 407 | 0.030 |
Why?
|
| Iodobenzenes | 1 | 1992 | 23 | 0.030 |
Why?
|
| Brain | 2 | 2018 | 27097 | 0.030 |
Why?
|
| Lymphedema | 1 | 1999 | 523 | 0.020 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2011 | 25 | 0.020 |
Why?
|
| Outpatients | 2 | 2011 | 1596 | 0.020 |
Why?
|
| Serum Albumin | 1 | 1995 | 674 | 0.020 |
Why?
|
| Maleimides | 1 | 1992 | 112 | 0.020 |
Why?
|
| Aorta, Abdominal | 2 | 1991 | 625 | 0.020 |
Why?
|
| Astrocytoma | 1 | 1996 | 774 | 0.020 |
Why?
|
| Focal Infection | 1 | 1991 | 9 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2017 | 1395 | 0.020 |
Why?
|
| Injections, Intralesional | 3 | 1998 | 280 | 0.020 |
Why?
|
| Endometritis | 1 | 1991 | 49 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1991 | 206 | 0.020 |
Why?
|
| Goats | 1 | 1991 | 165 | 0.020 |
Why?
|
| Morpholines | 1 | 2014 | 581 | 0.020 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 1990 | 66 | 0.020 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2012 | 1405 | 0.020 |
Why?
|
| Pentetic Acid | 1 | 1991 | 209 | 0.020 |
Why?
|
| Radiation Dosage | 2 | 1997 | 1966 | 0.020 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2011 | 151 | 0.020 |
Why?
|
| Platelet Aggregation | 2 | 1991 | 771 | 0.020 |
Why?
|
| Belgium | 1 | 2010 | 118 | 0.020 |
Why?
|
| Gangliosides | 1 | 1991 | 132 | 0.020 |
Why?
|
| Platelet Activation | 2 | 1991 | 646 | 0.020 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 166 | 0.020 |
Why?
|
| Rhodamine 123 | 1 | 1989 | 37 | 0.020 |
Why?
|
| Organotechnetium Compounds | 1 | 1990 | 132 | 0.020 |
Why?
|
| Aminopyridines | 1 | 2014 | 573 | 0.020 |
Why?
|
| Xanthenes | 1 | 1989 | 71 | 0.020 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 517 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 17889 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2007 | 12951 | 0.020 |
Why?
|
| Ascites | 1 | 1991 | 338 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 899 | 0.020 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2009 | 40 | 0.020 |
Why?
|
| Immunity | 1 | 2015 | 996 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6482 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1989 | 212 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2012 | 2898 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 1223 | 0.020 |
Why?
|
| Rhodamines | 1 | 1989 | 178 | 0.020 |
Why?
|
| Carcinoma | 1 | 2001 | 2328 | 0.020 |
Why?
|
| Prostate | 1 | 2017 | 1772 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1989 | 138 | 0.020 |
Why?
|
| Selenium Radioisotopes | 1 | 1988 | 13 | 0.020 |
Why?
|
| Selenomethionine | 1 | 1988 | 18 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 694 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2012 | 348 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2015 | 1361 | 0.020 |
Why?
|
| Niacinamide | 1 | 2011 | 413 | 0.020 |
Why?
|
| Endothelium, Vascular | 2 | 1991 | 4421 | 0.020 |
Why?
|
| Triazoles | 1 | 2014 | 903 | 0.020 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2009 | 164 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2012 | 559 | 0.020 |
Why?
|
| Neoplasm Seeding | 1 | 2008 | 84 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2015 | 1528 | 0.020 |
Why?
|
| Embolism | 1 | 1991 | 399 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2012 | 1768 | 0.020 |
Why?
|
| Antibodies | 2 | 1995 | 2415 | 0.020 |
Why?
|
| Neurofibromatoses | 1 | 2011 | 299 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 3869 | 0.020 |
Why?
|
| Fibrosarcoma | 1 | 1989 | 308 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 1991 | 851 | 0.020 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2011 | 380 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2010 | 998 | 0.020 |
Why?
|
| Succimer | 1 | 1987 | 31 | 0.020 |
Why?
|
| Sodium Pertechnetate Tc 99m | 1 | 1987 | 54 | 0.020 |
Why?
|
| Nose Neoplasms | 1 | 2009 | 249 | 0.020 |
Why?
|
| Abscess | 1 | 1991 | 605 | 0.020 |
Why?
|
| Technetium Tc 99m Dimercaptosuccinic Acid | 1 | 1987 | 81 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2017 | 2599 | 0.020 |
Why?
|
| Technetium | 1 | 1987 | 326 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2023 | 54419 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2009 | 590 | 0.020 |
Why?
|
| Dimerization | 1 | 2007 | 888 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2010 | 877 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 2208 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 1991 | 6123 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2008 | 713 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 1577 | 0.020 |
Why?
|
| Methotrexate | 1 | 2012 | 1717 | 0.020 |
Why?
|
| Internet | 1 | 2017 | 3094 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2000 | 4795 | 0.020 |
Why?
|
| Angiography | 1 | 1990 | 1597 | 0.020 |
Why?
|
| Stomach | 1 | 2009 | 697 | 0.020 |
Why?
|
| Granulocytes | 1 | 1987 | 550 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2009 | 8519 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2008 | 982 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 3689 | 0.010 |
Why?
|
| DNA | 1 | 1998 | 7189 | 0.010 |
Why?
|
| Bone Remodeling | 1 | 2008 | 583 | 0.010 |
Why?
|
| Adenocarcinoma | 2 | 1993 | 6340 | 0.010 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1987 | 577 | 0.010 |
Why?
|
| Clone Cells | 1 | 2007 | 1667 | 0.010 |
Why?
|
| Apnea | 1 | 1985 | 195 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 2635 | 0.010 |
Why?
|
| Reflex | 1 | 1985 | 375 | 0.010 |
Why?
|
| Heart Failure | 1 | 2007 | 11701 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1987 | 1535 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2007 | 1487 | 0.010 |
Why?
|
| Advisory Committees | 1 | 2007 | 788 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2010 | 1834 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 2465 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 1702 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 793 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 11066 | 0.010 |
Why?
|
| Incidence | 2 | 2011 | 21357 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2008 | 1264 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2009 | 4014 | 0.010 |
Why?
|
| Osteogenesis | 1 | 2008 | 1272 | 0.010 |
Why?
|
| Heterozygote | 1 | 2008 | 2778 | 0.010 |
Why?
|
| CHO Cells | 1 | 2003 | 1379 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1703 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 3779 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1991 | 2477 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 1681 | 0.010 |
Why?
|
| Intestines | 1 | 2009 | 1908 | 0.010 |
Why?
|
| Cricetinae | 1 | 2003 | 2412 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1997 | 42217 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6067 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1985 | 2666 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 1151 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 2217 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1988 | 6198 | 0.010 |
Why?
|
| Ethanol | 1 | 1985 | 1322 | 0.010 |
Why?
|
| Risk Factors | 2 | 2009 | 74219 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2007 | 1882 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 2165 | 0.010 |
Why?
|
| Thigh | 1 | 1999 | 239 | 0.010 |
Why?
|
| Lymphography | 1 | 1999 | 188 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 1743 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2013 | 9317 | 0.010 |
Why?
|
| Sarcoma, Synovial | 1 | 1999 | 153 | 0.010 |
Why?
|
| Crohn Disease | 1 | 1991 | 2279 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 1999 | 287 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1989 | 2528 | 0.010 |
Why?
|
| Chondrosarcoma | 1 | 1999 | 295 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2008 | 5249 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2223 | 0.010 |
Why?
|
| Massachusetts | 1 | 2009 | 8836 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2013 | 7844 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6224 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2009 | 5971 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 5750 | 0.010 |
Why?
|
| Isoelectric Point | 1 | 1995 | 76 | 0.010 |
Why?
|
| Stereotaxic Techniques | 1 | 1998 | 555 | 0.010 |
Why?
|
| Glioma | 1 | 1990 | 3452 | 0.010 |
Why?
|
| Sepharose | 1 | 1995 | 102 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2003 | 4109 | 0.010 |
Why?
|
| Comorbidity | 1 | 2009 | 10514 | 0.010 |
Why?
|
| Child | 3 | 2009 | 80134 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1997 | 15634 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1998 | 2010 | 0.010 |
Why?
|
| Cause of Death | 1 | 2005 | 3688 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2007 | 5520 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 10421 | 0.010 |
Why?
|
| Sheep | 2 | 1987 | 1436 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 1993 | 6919 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 8303 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 9416 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2007 | 8478 | 0.010 |
Why?
|
| Drug Stability | 1 | 1992 | 288 | 0.010 |
Why?
|
| Immunologic Capping | 1 | 1991 | 30 | 0.010 |
Why?
|
| Cell Line | 3 | 1990 | 15542 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1992 | 319 | 0.010 |
Why?
|
| Cecal Diseases | 1 | 1991 | 49 | 0.010 |
Why?
|
| Ligation | 1 | 1991 | 446 | 0.010 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1989 | 71 | 0.010 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1990 | 183 | 0.010 |
Why?
|
| Cations | 1 | 1990 | 238 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1991 | 714 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 1990 | 387 | 0.010 |
Why?
|
| Acute Disease | 1 | 1999 | 7240 | 0.000 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 3803 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2009 | 24013 | 0.000 |
Why?
|
| Dithioerythritol | 1 | 1987 | 8 | 0.000 |
Why?
|
| Acetic Acid | 1 | 1987 | 59 | 0.000 |
Why?
|
| Thromboxane B2 | 1 | 1987 | 143 | 0.000 |
Why?
|
| Femoral Artery | 1 | 1991 | 826 | 0.000 |
Why?
|
| Membrane Potentials | 1 | 1990 | 1089 | 0.000 |
Why?
|
| Leukopenia | 1 | 1987 | 213 | 0.000 |
Why?
|
| Hydroxyurea | 1 | 1987 | 284 | 0.000 |
Why?
|
| Diving | 1 | 1985 | 43 | 0.000 |
Why?
|
| Acetates | 1 | 1987 | 319 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1989 | 1391 | 0.000 |
Why?
|
| Antibody Specificity | 1 | 1987 | 1057 | 0.000 |
Why?
|
| Infant | 1 | 1987 | 36164 | 0.000 |
Why?
|
| Trigeminal Nerve | 1 | 1985 | 248 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1991 | 2926 | 0.000 |
Why?
|
| Capillary Permeability | 1 | 1987 | 773 | 0.000 |
Why?
|
| Kinetics | 1 | 1990 | 6312 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1991 | 2413 | 0.000 |
Why?
|
| Transplantation, Heterologous | 1 | 1989 | 2381 | 0.000 |
Why?
|
| Oxidation-Reduction | 1 | 1987 | 2227 | 0.000 |
Why?
|
| Larynx | 1 | 1985 | 492 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1990 | 3665 | 0.000 |
Why?
|
| Temperature | 1 | 1987 | 2219 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2002 | 23415 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1987 | 3936 | 0.000 |
Why?
|
| Respiration | 1 | 1985 | 1656 | 0.000 |
Why?
|
| Hypertension, Pulmonary | 1 | 1987 | 1585 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1985 | 4164 | 0.000 |
Why?
|
| Models, Biological | 1 | 1990 | 9455 | 0.000 |
Why?
|